Skip to main content

Advertisement

SpringerLink
Log in

Current therapies in Hodgkin's disease

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tubiana M, Henry-Amar M, Hayat M, et al. The EORTC treatment of early stages of Hodgkin's disease. The role of radiotherapy. Int J Radiat Oncol Biol Phys 1984; 10:197–206.

    CAS  PubMed  Google Scholar 

  2. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11:2258–2272.

    CAS  PubMed  Google Scholar 

  3. Sutcliffe SB, Gospodarowicz MK, Bergsagel DE, et al. Prognostic groups for the management of localized Hodgkin's disease. J Clin Oncol 1985; 3:393–401.

    CAS  PubMed  Google Scholar 

  4. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC lymphoma group controlled trials: 1964–1987. Blood 1989; 73:47–56.

    CAS  PubMed  Google Scholar 

  5. Ganesan T, Wrigley PF, Murray PA, et al. Radiotherapy for stage I Hodgkin's disease. 20 years experience at St. Bartholomew's Hospital. Br J Cancer 1990; 2:314–318.

    Google Scholar 

  6. Zittoun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 1985; 2:207–214.

    Google Scholar 

  7. Bonfante V, Viviani S, Devizzi V, et al. Ten-years experience with ABVD plus radiotherapy: subtotal nodal irradiation (STNI) vs involved-field (IFRT) in early stage Hodgkin's disease [abstract]. Proc Am Soc Clin Oncol 2001; 20:281a.

    Google Scholar 

  8. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002; 13 Suppl 1:79–83.

    Google Scholar 

  9. Hagenbeek A, Carde P, Noordijk E, et al. Prognostic factor tailored treatment of early stage Hodgkin's disease. Results of a prospective randomized phase III clinical trial in 762 patients (H7 study). Blood 1997; 15:1736–1744.

    Google Scholar 

  10. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA. Vinblastine, bleomycin and methotrexate: an effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 1988; 6:1822–1831.

    CAS  PubMed  Google Scholar 

  11. Horning SF, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997; 15:1736–1744.

    CAS  PubMed  Google Scholar 

  12. Radford JA, Cowan RA, Ryder WDJ, et al. Four weeks of neoadjuvant chemotherapy significantly reduce the progression rate in patients treated with limited field radiotherapy for clinical stage IA/IIA Hodgkin's disease. Ann Oncol 1996; 7 Suppl 3:21.

    Google Scholar 

  13. Longo DL, Glatstein E, Duffey PL, et al. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven year results of a prospective randomized trial. J Clin Oncol 1991; 9:906–917.

    CAS  PubMed  Google Scholar 

  14. Biti GP, Cimino G, Cartoni C, et al. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin's disease: eight year update of an Italian prospective randomized study. J Clin Oncol 1992; 10:378–382.

    CAS  PubMed  Google Scholar 

  15. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin's disease. J Natl Cancer Inst 1988; 80:1466–1473.

    CAS  PubMed  Google Scholar 

  16. Wiedenmann S, Schiller P, Paulus U, Wolf J. Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group. Ann Oncol 2002; 13 Suppl 1: 84–85.

    Google Scholar 

  17. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood 1989; 73:47–56.

    CAS  PubMed  Google Scholar 

  18. Bartlett N, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995; 13:1080–1088.

    CAS  PubMed  Google Scholar 

  19. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective trial. J Clin Oncol 2002; 20:630–637.

    Article  PubMed  Google Scholar 

  20. DeVita VT, Serpick A. Combination chemotherapy in the treatment of Hodgkin's disease [abstract]. Proc Am Assoc Cancer Res 1967; 8:13.

    Google Scholar 

  21. Wagstaff J, Gregory WM, Swindell R, Crowther D, Lister TA. Prognostic factors for survival in stage IIIb and IV Hodgkin's disease: a multicentre analysis comparing two specialist treatment centers. Br J Cancer 1988; 58:487–492.

    CAS  PubMed  Google Scholar 

  22. The International ChlVPP Treatment Group. ChlVPP therapy for Hodgkin's disease: experience of 960 patients. Ann Oncol 1995; 6:167–172.

    PubMed  Google Scholar 

  23. Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Haybittle JL, Bennett MH, MacLennan KA, Jelliffe AM. British National Lymphoma Investigation randomized study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran, Oncovin, procarbazine, prednisolone) in advanced Hodgkin's disease—long term results. Br J Cancer 1991; 63:579–582.

    CAS  PubMed  Google Scholar 

  24. Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med 1982; 96:139–144.

    CAS  PubMed  Google Scholar 

  25. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. Ann Intern Med 1986; 104:739–745.

    CAS  PubMed  Google Scholar 

  26. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478–1484.

    CAS  PubMed  Google Scholar 

  27. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339:1506–1514.

    Article  CAS  PubMed  Google Scholar 

  28. Levis A, Bobbi PG, Chisesi T, et al. ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma. Results of a randomized trial [abstract]. Ann Oncol 2002; 13 Suppl 2:25.

    Google Scholar 

  29. Chisesi T, Federico M, Levis A, et al. ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomized trial. Ann Oncol 2002; 13 Suppl 1:102–106.

    Google Scholar 

  30. Tesch H, Diehl V, Lathan B, et al. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood 1998; 12:4560–4567.

    Google Scholar 

  31. Diehl V, Franklin J, Hasenclever D, et al. BEACOPP, a new dose-escalated and accelerated regimen, is a least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16:3810–3821.

    CAS  PubMed  Google Scholar 

  32. Diehl V, Franklin J, Paulus U,et al. Dose escalated BEACOPP chemotherapy regimen for advanced Hodgkin's disease: final analysis of the HD9 randomised trial of the GHSG [abstract]. Ann Oncol 2002; 13 Suppl 2:25.

    Google Scholar 

  33. Franklin J, Diehl V. Current clinical trials for the treatment of advanced-stage Hodgkin's disease: BEACOPP. Ann Oncol 2002; 13 Suppl 1:98–101.

    Google Scholar 

  34. Connors JM. Current clinical trials for advanced Hodgkin's lymphoma in North America: history, design, and rationale. Ann Oncol 2002; 13 Suppl 1:92–95.

    Google Scholar 

  35. Longo DL, Russo A, Duffey PL, et al. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. J Clin Oncol 1991; 9:227–235.

    CAS  PubMed  Google Scholar 

  36. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. Ann Intern Med 1994; 120:903–912.

    CAS  PubMed  Google Scholar 

  37. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. J Clin Oncol 1998; 16:818–829.

    CAS  PubMed  Google Scholar 

  38. Federico M, Carella A, Brice P, et al. High dose therapy (HDT) and autologous stem cell transplantation (ASCT) versus conventional therapy for patients with advanced Hodgkin's disease (HD) responding to initial therapy [abstract]. Proc Am Soc Clin Oncol 2002;

  39. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341:1050–1054.

    Google Scholar 

  40. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359:2065–2071.

    Article  CAS  PubMed  Google Scholar 

  41. Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide and prednisone (CEP) in refractory Hodgkin's disease. Semin Oncol 1986; 12 Suppl 1:23–26.

    Google Scholar 

  42. Longo DL, Duffey PL, Young RC, et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10:210–218.

    CAS  PubMed  Google Scholar 

  43. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89:814–822.

    CAS  PubMed  Google Scholar 

  44. Lazarus HM, Rowlings PA, Zhang MJ, et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 1999; 17:534–545.

    CAS  PubMed  Google Scholar 

  45. Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. J Clin Oncol 1999; 17:3101–3109.

    PubMed  Google Scholar 

  46. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996; 14:1291–1296.

    CAS  PubMed  Google Scholar 

  47. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77:649–653.

    CAS  PubMed  Google Scholar 

  48. Anderson JE, Litzow MR, Appelbaum FR, et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993; 11:2342–2350.

    CAS  PubMed  Google Scholar 

  49. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's disease. J Clin Oncol 2001; 19:4314–4321.

    CAS  PubMed  Google Scholar 

  50. Schnell R, Borchmann P, Schulz H, Engert A. Current strategies of antibody-based treatment in Hodgkin's disease. Ann Oncol 2002; 13 Suppl 1:57–66.

    Google Scholar 

  51. Lucas JB, Hoppe RT, Horwitz SM, et al. Rituximab is active in lymphocyte predominance Hodgkin's disease. Blood 2000; 96 Suppl 11:abstract 3592.

  52. Schulz H, Rehwald U, Reiser V, Enger A, on behalf of the German Hodgkin Lymphoma Study Group (GHSG). The monoclonal antibody rituximab is well tolerated and extremely effective in the treatment of relapsed CD-20 positive Hodgkin's lymphoma–an update [abstract]. Ann Oncol 2002; 13 Suppl 2:63.

    Google Scholar 

  53. Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000; 14:129–135.

    Article  CAS  PubMed  Google Scholar 

  54. Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339:1195–1196.

    CAS  PubMed  Google Scholar 

  55. Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22×Ki-4 in patients with refractory Hodgkin lymphoma. Blood 2002; 100:3101–3107.

    Article  CAS  PubMed  Google Scholar 

  56. Lenhard RE Jr, Order SE, Spunberg JJ, Asbell SO, Leibel SA. Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985; 3:1296–1300.

    PubMed  Google Scholar 

  57. Vriesendorp HM, Quadri SM, Wyllie CT, et al. Fractionated radio-labeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 1999; 5 Suppl 10:3324S–3329S.

    Google Scholar 

  58. Henry-Amar M, Somers R. Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease. Semin Oncol 1990; 17:758–768.

    CAS  PubMed  Google Scholar 

  59. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6:225–242.

    PubMed  Google Scholar 

  60. Lund MB, Kongerud J, Nome O, Abrahamsen AF, Bjortuft O, Forfang K, Boe J. Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol 1995; 6:495–501.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, University of Colorado Health Sciences Centre, 4200 East 9th Avenue, F704, Denver, CO 80262, USA

    K. E. Kogel & J. W. Sweetenham

Authors
  1. K. E. Kogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. W. Sweetenham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. W. Sweetenham.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kogel, K.E., Sweetenham, J.W. Current therapies in Hodgkin's disease. Eur J Nucl Med Mol Imaging 30 (Suppl 1), S19–S27 (2003). https://doi.org/10.1007/s00259-003-1156-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-003-1156-7

Keywords

Search

Navigation